GSA Capital Partners LLP bought a new position in Insulet Co. (NASDAQ:PODD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 25,679 shares of the medical instruments supplier’s stock, valued at approximately $1,414,000.
Other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in Insulet by 19.9% in the second quarter. Russell Investments Group Ltd. now owns 29,054 shares of the medical instruments supplier’s stock worth $1,491,000 after acquiring an additional 4,824 shares during the period. Strs Ohio lifted its position in Insulet by 35.0% during the second quarter. Strs Ohio now owns 5,400 shares of the medical instruments supplier’s stock valued at $277,000 after buying an additional 1,400 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Insulet by 3.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 252,670 shares of the medical instruments supplier’s stock valued at $12,965,000 after buying an additional 8,399 shares during the period. SG Americas Securities LLC purchased a new position in Insulet during the second quarter valued at $180,000. Finally, Bank of New York Mellon Corp lifted its position in Insulet by 0.7% during the second quarter. Bank of New York Mellon Corp now owns 270,916 shares of the medical instruments supplier’s stock valued at $13,901,000 after buying an additional 2,006 shares during the period.
PODD has been the subject of several recent research reports. Barclays initiated coverage on Insulet in a research report on Friday, September 15th. They set an “overweight” rating and a $65.00 price objective for the company. Canaccord Genuity reaffirmed a “hold” rating and issued a $50.00 price target on shares of Insulet in a research report on Wednesday, September 27th. Zacks Investment Research downgraded Insulet from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. Wedbush restated a “buy” rating and set a $65.00 price target (up from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Finally, Leerink Swann reiterated an “outperform” rating and set a $74.00 price objective (up from $65.00) on shares of Insulet in a research note on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. Insulet has an average rating of “Buy” and a consensus target price of $62.53.
Shares of Insulet Co. (PODD) traded up $1.47 during trading on Thursday, reaching $77.30. The company’s stock had a trading volume of 643,250 shares, compared to its average volume of 763,731. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. The company has a market cap of $4,410.00, a P/E ratio of -154.60 and a beta of 1.58. Insulet Co. has a 12 month low of $38.43 and a 12 month high of $78.65.
Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The company had revenue of $121.80 million during the quarter, compared to analysts’ expectations of $114.02 million. During the same period last year, the business posted ($0.05) earnings per share. The firm’s revenue was up 28.4% compared to the same quarter last year. equities analysts anticipate that Insulet Co. will post -0.43 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2018/01/11/gsa-capital-partners-llp-takes-1-41-million-position-in-insulet-co-podd.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.